Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Showing 1-25 of 29 citing articles:

Cardiovascular benefits of SGLT2 inhibitors and GLP-1 receptor agonists through effects on mitochondrial function and oxidative stress
Clara Luna-Marco, Francesca Iannantuoni, Alberto Hermo-Argibay, et al.
Free Radical Biology and Medicine (2024) Vol. 213, pp. 19-35
Open Access | Times Cited: 28
The Role of Oxidative Stress in Kidney Injury
Nejc Piko, Sebastjan Bevc, Radovan Hojs, et al.
Antioxidants (2023) Vol. 12, Iss. 9, pp. 1772-1772
Open Access | Times Cited: 29
Targeting redox imbalance in neurodegeneration: characterizing the role of GLP-1 receptor agonists
Puja Ghosh, Rosaria Anna Fontanella, Lucia Scisciola, et al.
Theranostics (2023) Vol. 13, Iss. 14, pp. 4872-4884
Open Access | Times Cited: 25
Effects of Glucagon‐Like Peptide‐1 Receptor Agonists, Sodium‐Glucose Cotransporter‐2 Inhibitors, and Their Combination on Neurohumoral and Mitochondrial Activation in Patients With Diabetes
Ignatios Ikonomidis, George Pavlidis, Loukia Pliouta, et al.
Journal of the American Heart Association (2025)
Open Access | Times Cited: 1
Antioxidant Roles of SGLT2 Inhibitors in the Kidney
Carmen Llorens-Cebrià, Mireia Molina-Van den Bosch, Ander Vergara, et al.
Biomolecules (2022) Vol. 12, Iss. 1, pp. 143-143
Open Access | Times Cited: 29
Effects of Liraglutide, Empagliflozin and Their Combination on Left Atrial Strain and Arterial Function
Κ Katogiannis, J Thymis, Foteini Kousathana, et al.
Medicina (2024) Vol. 60, Iss. 3, pp. 395-395
Open Access | Times Cited: 7
The effect of EMPAgliflozin on markers of inflammation in patients with concomitant type 2 diabetes mellitus and Coronary ARtery Disease: the EMPA-CARD randomized controlled trial
Sepehr Gohari, Tara Reshadmanesh, Hadi Khodabandehloo, et al.
Diabetology & Metabolic Syndrome (2022) Vol. 14, Iss. 1
Open Access | Times Cited: 23
The importance of microvascular inflammation in ageing and age-related diseases: a position paper from the ESH working group on small arteries, section of microvascular inflammation
Alessandro Mengozzi, Carolina De Ciuceis, Raffaella Dell’Oro, et al.
Journal of Hypertension (2023) Vol. 41, Iss. 10, pp. 1521-1543
Open Access | Times Cited: 12
THE ROLE OF OXIDATIVE STRESS IN CHRONIC KIDNEY DISEASE (CKD)
Ara Aboolian, Joe Younes, Alejandra Romero, et al.
(2025), pp. 417-436
Closed Access
Therapeutic Effects of GLP-1 Receptor Agonists and DPP-4 Inhibitors in Neuropathic Pain: Mechanisms and Clinical Implications
Yaswanth Kuthati, Venkata Naga Goutham Davuluri, Chih‐Shung Wong
Biomolecules (2025) Vol. 15, Iss. 5, pp. 622-622
Open Access
BIOMARKERS OF OXIDATIVE STRESS IN NEURODEGENERATIVE DISEASES
Rukhsana Sultana, Giovanna Cenini, D. Allan Butterfield
(2025), pp. 437-454
Closed Access
Different formulations of semaglutide and oxidative stress in subjects with type 2 diabetes and MASLD: an open-label, real-life study
Giovanni Petralli, Alice Del Zoppo, Chiara Rovera, et al.
Acta Diabetologica (2025)
Closed Access
SGLT2 Inhibitors in Aging-Related Cardiovascular Disease: A Review of Potential Mechanisms
Yali Zhang, Yufeng He, Siqi Liu, et al.
American Journal of Cardiovascular Drugs (2023) Vol. 23, Iss. 6, pp. 641-662
Closed Access | Times Cited: 7
A Study to Evaluate the Effect of Sodium-Glucose Co-transporter 2 (SGLT2) Inhibitors on Oxidative Stress Parameters in Type 2 Diabetes Mellitus Patients
Ankita Sharma, D Aruna, Anne Beatrice
Cureus (2024)
Open Access | Times Cited: 2
Semaglutide Concurrently Improves Vascular and Liver Indices in Patients With Type 2 Diabetes and Fatty Liver Disease
Emmanouil Korakas, Aikaterini Kountouri, George Pavlidis, et al.
Journal of the Endocrine Society (2024) Vol. 8, Iss. 8
Open Access | Times Cited: 2
Antidiabetic Treatment and Prevention of Ischemic Stroke: A Systematic Review
V Prentza, George Pavlidis, Ignatios Ikonomidis, et al.
Journal of Clinical Medicine (2024) Vol. 13, Iss. 19, pp. 5786-5786
Open Access | Times Cited: 2
Oxidative Stress and Antioxidant Therapy in Cardiovascular Diseases—Clinical Challenge
George Pavlidis
Journal of Clinical Medicine (2022) Vol. 11, Iss. 13, pp. 3784-3784
Open Access | Times Cited: 10
Anti-Diabetic Therapy, Heart Failure and Oxidative Stress: An Update
Ioanna Koniari, Dimitrios Velissaris, Nicholas G. Kounis, et al.
Journal of Clinical Medicine (2022) Vol. 11, Iss. 16, pp. 4660-4660
Open Access | Times Cited: 10
Oxidative Stress Management in Cardiorenal Diseases: Focus on Novel Antidiabetic Agents, Finerenone, and Melatonin
Panagiotis Theofilis, Aikaterini Vordoni, Rigas Kalaitzidis
Life (2022) Vol. 12, Iss. 10, pp. 1663-1663
Open Access | Times Cited: 10
The vicious circle of arterial elasticity, blood pressure, glycemia, and renal function
Ignatios Ikonomidis, J Thymis
Hypertension Research (2023) Vol. 46, Iss. 6, pp. 1599-1602
Open Access | Times Cited: 6
Redox regulation in diabetic kidney disease
Ilse S. Daehn, Ubong S. Ekperikpe, Krisztián Stadler
AJP Renal Physiology (2023) Vol. 325, Iss. 2, pp. F135-F149
Open Access | Times Cited: 6
GLP-1 receptor agonists and SGLT2 inhibitors: new anti-aging tools?
Gaetano Santulli, Pasquale Mone, Fahimeh Varzideh
Future Cardiology (2024), pp. 1-4
Open Access | Times Cited: 1
Comparisons of pleiotropic effects of SGLT2 inhibition and GLP-1 agonism on cardiac glucose intolerance in heart dysfunction
Belma Turan, Ayşegül Durak, Yusuf Olğar, et al.
Molecular and Cellular Biochemistry (2022) Vol. 477, Iss. 11, pp. 2609-2625
Closed Access | Times Cited: 5
EVOO’s Effects on Incretin Production: Is There a Rationale for a Combination in T2DM Therapy?
Simona Amodeo, Luigi Mirarchi, Aurelio Seidita, et al.
International Journal of Molecular Sciences (2022) Vol. 23, Iss. 17, pp. 10120-10120
Open Access | Times Cited: 3
Multiple Benefits of Empagliflozin in PCOS: Evidence from a Preclinical Rat Model
Dejana Rakic, Vladimir Jakovljević, Vladimir Živković, et al.
Pathophysiology (2024) Vol. 31, Iss. 4, pp. 559-582
Open Access
Page 1 - Next Page

Scroll to top